Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT).
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group forced up-titration
study. Randomization will be stratified according to the patient's baseline serum sodium
concentration (137-144 and <137 mmol/L). The dose of study drug will be increased to the next
level on Day 15, and the total duration of the double-blind treatment period is 120 days.